Phase I and II Study of ASP8273 - An Open-label Study of the Oral Administration of ASP8273 in Patients With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Trial Profile

Phase I and II Study of ASP8273 - An Open-label Study of the Oral Administration of ASP8273 in Patients With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 15 Jul 2017

At a glance

  • Drugs Naquotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 10 May 2017 According to an Astellas Pharma media release, based on the recommendation by the Independent Data Monitoring Committee (IDMC), the company is discontinuing the ASP8273 program. No new patients will be enrolled in ASP8273 trials and all patients currently receiving ASP8273 are encouraged to speak with their physician about their treatment.
    • 10 May 2017 Status changed from active, no longer recruiting to discontinued, as reported in an Astellas Pharma media release.
    • 25 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top